Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing therapies for neurodegenerative and metabolic disorders, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage. Durkacz noted that current treatments do not adequately address this unmet need.
Durkacz also highlighted Quantum BioPharma's commercial alcohol metabolism product, unbuzzd, designed to accelerate blood alcohol metabolism and currently available in the U.S. market. The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets the over-the-counter version, and receives royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains full rights for pharmaceutical and medical uses.
Looking ahead, Quantum BioPharma is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients, following Phase 1 testing in healthy volunteers. The company believes Lucid-MS has the potential to prevent and reverse myelin degradation, the underlying mechanism of MS, based on preclinical models.
For more details, the full press release is available at https://ibn.fm/HURxt. Additional information about Quantum BioPharma can be found in the company's newsroom at https://ibn.fm/QNTM.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company focuses on research and development of Lucid-MS, a patented new chemical entity. The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans.
